You are here
VIDAS® Hepatitis panel
Routine and confirmation testing of Hepatitis A, B, C and E
The VIDAS® Hepatitis panel includes 11 markers for the diagnosis of recent infection, monitoring of chronic hepatitis, pre- or post-vaccination immunity controls and screening during pregnancy.
- Comprehensive panel for the differential diagnosis of hepatitis
- Rapid, simple and reliable testing in less than 2 hours
- Flexible and cost-effective solution
- Includes hepatitis E testing in only 40 minutes
Add to my selection
Do you need more information
Viral hepatitis affects over 500 million people worldwide. With prevalence higher than that of HIV or cancer, it represents one of the major global health problems. The role of diagnostics is key as hepatitis infections are “silent” and the majority of those infected are unaware.
The VIDAS® Hepatitis panel includes 11 automated assays offering a complete solution for the diagnosis and monitoring of Hepatitis A, B, C and E. Used together, they enable clinicians to provide a differential diagnosis for patients presenting with symptoms suggestive of hepatitis.
A complete panel to address a complex clinical picture
Hepatitis, especially hepatitis B, presents a complex clinical picture. Various markers are necessary for accurate diagnosis and efficient monitoring:
Hepatitis B infection kinetics
Hepatitis A infection kinetics
Hepatitis C infection kinetics
Hepatitis E infection kinetics
The VIDAS® Hepatitis assays provide answers to different clinical situations:
-
Screening and aid to diagnosis of recent infection: HAV IgM, HBs Ag Ultra, HBc IgM II, Anti-HCV, Anti-HEV IgM
-
Monitoring of chronic hepatitis: HBs Ag Ultra, HBe/Anti-HBe, Anti-HBs Total II
-
Determination of hepatitis immune status (pre-post vaccination): Anti-HAV Total, Anti-HBs Total II, Anti-HBc Total II, Anti-HEV IgG
-
Screening during pregnancy: HBs Ag Ultra, Anti-HCV
Solution benefits
Easy to perform:
- Automated assays
- Load and Go
Cost-effective:
- Single-dose tests: 1 patient = 1 test = 1 result
- Convenient kit size: 30 or 60 tests
- All-inclusive kits
Reliable:
- The performance of each marker has been verified by reference laboratories
- No cross-contamination
- Robust system: MTBF>700 days
Expertise in Infectious Diseases
The history of bioMérieux is directly linked to the fight against infectious diseases, which has been our priority for 50 years. Our research teams constantly focus on pushing back the frontiers of disease detection by dedicating the majority of their activities to the prevention and diagnosis of infection risk.
bioMérieux provides tests for the early detection of numerous diseases, including HIV/AIDS, hepatitis, tuberculosis, respiratory infections, CNS infections, sepsis, C. difficile…
|
Parameter |
Reference |
Tests/kit |
Sample type |
Sample volume |
Time to result (minutes) |
Calibration frequency |
|
Hepatitis A |
||||||
| VIDAS® HAV IgM | 30307 | 30 | Serum, plasma (EDTA, Hep.) | 100 µL | 60 | 14 days |
| VIDAS® Anti-HAV Total | 30312 | 30 | Serum, plasma (Hep., EDTA, Cit.) | 150 µL | 90 | 14 days |
|
Hepatitis B |
||||||
| VIDAS® HBs Ag Ultra | 30315 | 60 | Serum, plasma (EDTA, Hep.) | 150 µL | 60(HBS) 90(HBL) |
14 days |
| VIDAS® HBs Ag Ultra Confirmation | 30317 | 30 | 14 days | |||
| VIDAS® Anti-HBs Total II | 30318 | 60 | Serum, plasma (Hep., EDTA, Cit.) | 200 µL | 60 | 28 days |
| VIDAS® Anti-HBc Total II | 30314 | 60 | Serum, plasma (Hep., EDTA, Cit.) | 150 µL | 90 | 14 days |
| VIDAS® HBc IgM II | 30439 | 30 | Serum, plasma (Hep., EDTA, Cit.) | 100 µL | 55 | 14 days |
| VIDAS® HBe/Anti-HBe | 30305 | 30 | Serum, plasma (Hep., EDTA, Cit.) | 150 µL | 90 | 14 days |
|
Hepatitis C |
||||||
| VIDAS® Anti-HCV | 30308 | 60 | Serum, plasma (Hep.) | 100 µL | 40 | 28 days |
| VIDAS® Anti-HCV IgM | 418115 | 30 | Serum, plasma | 100 µL | 40 | 28 days |
| VIDAS® Anti-HCV IgG | 418116 | 30 | Serum, plasma | 100 µL | 40 | 28 days |
Consult your local bioMérieux representative for product availability in your country.
Related Publications
- Abravanel F, et al, Performance evaluation of new automated immunoassay tests, VIDAS® Anti-HEV IgM and IgG assays, in European and non-European populations, ESCV 2017
- Salvetti S, Lavinia F, Montenora I, Performance del kit per la determinazione di anticorpi anti-HCV sul sistema automatizzato VIDAS, Associazione Microbiologi Clinici Italiani (AMCLI) 2013, November 12-15, Rimini, Italy
- Servant-Delmas A, et al, Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples, Journal of Clinical Virology, 53 (2012) 338– 345
- Seigneres B, et al, Performance evaluation of VIDAS® Anti-HCV, a new automated immunoassay test for the qualitative detection of antibodies anti-HCV in human serum and plasma samples, ECCMID 2012, March 31-April 3, London, United Kingdom
- Seignères B, et al, Sensitivity and specificity evaluation of a new automated immunoassay test, VIDAS® Anti-HCV, for the qualitative detection of antibodies anti-HCV in human samples, ISVHLD 2012, June 22-25, Shanghai, China
Useful Links
